Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Interesting article in today's bus section. Onyx pharma is buying "cancer drug developer Proteolix Inc in a deal that could be worth as much as $851 MILLION".
hmmm think I'll grab some more. This is the right place to hit the home run> IMHO, GLTA
Mixed results today: all trades on bid .062 (but only 6K+ shares.
Here's the interesting situation: The offer is .079 and the next offer showing on LII is .12.
Talk about frustrating! Thought we were "on the way", but today tells a different story.
Mrbrick, don't be a stranger. The last 2 days trade has been very encouraging. Early in the week stock was being pizzed away @ .06 & .055 and now the buyer is being agressive and willing to pay .08 for shares. HMMM. The question is WHY??
GLTY
Thanks chilar, I've been here with you a long time. This does have a great potential. I don't talk much.
I'm tired of talking to myself, BUT, if anyone else cares: SOMETHIN'S GOIN ON!
Someone (besides me, LOL)wants this puppy higher & is getting agressive on the bid trying to accumulate size.
Nice to have company. The bid, TODAY, was raised from .065 to .07 and purposely closed @ .08. Probably to keep the account looking good re all the shares grabbed yesterday.
Or, someone is anticipating news VERY SOON.
JMHO, GLTA
what done happened today???? NO NEWS!
i AINT BITCHEN. LOL
EddieH, if my order is an open order that has been there for several days, there should be no way it isn't there before the opening. IMO.
Of course, what the he11 do I know??
unfortunately, your MM goes on the bid at the open, and there is a second or two that a sell can scoot in before your bid shows up.
2 DAYS IN A ROW THE BASTURDS OPENED @ .055, 1/2 CENT BELOW THE BID.
if a broker is selling retail shares, he should be stripped of license for breach of fiduciary responsibility.
If it's a MM playing games (with me), my response to him is "FU, AH".
lol
"pees me off mon" ! They opend the stock below my bid this morning on a small odd lot> LOL
I responded by increasing the size and price of my bid.
SUCCESS!!! BTW, welcome to the board, I've been tired of talking to myself. If you read my posts, you'll learn I have a substantial position and very gerat expectations for this puppy.
BTW, I was not the buyer that closed the pps up, so there are others around who would like to see pps increase.
GLTY
daynwyus, will work on it. I'm not a paid member and am surprised they would let a non payor be mod.
That's strange, I've been de-moderated from a board, but never heard of being involuntary moderated.
To place a sticky:
Near the “Post New Message” button , above the Dark Blue bar that separates the “Message Field” from the Stock chart and price quotes graphics you will see the “MANAGE” button next to “HANGOUT” button. Click Manage and look for Manage StickyPost , Click it and put 214 in the Add POST# window, Click AddPost button on right.
dayneyus, don't know how to do it. LOL
I'm not really the mod & don't know how that got there.
Lucky I can figger out how to post.
Nite playing games with me today.
Think I'll have the last laugh.
GLTY
Interesting to note, ABLE is on the bid for several days and showing no signs of "filling". So far they've gobbled up everything they can @ .055.
Next news, we fly! IMO
This is strictly my opinion: I think GW is working on a partnership deal or perhaps a buy out with any one of several bio companies once the delivery systemis finalized.
HAVE NOT SPOKEN TO GW IN A LONG TIME, SO THE ABOVE IS ONLY MY OPINION. OR PERHAPS HOPES.
GLTA
These guys ain't too shabby:
The Latitude Team
Andrew X. Chen, PhD, RPh, President. Dr. Chen founded Latitude Pharmaceuticals, Inc. in 2003 to address the difficult formulation challenges facing biotech and pharmaceutical companies. Andrew has over 20 years of formulation experience covering small molecule, peptide, protein, nucleic acid, and virus-based pharmaceuticals. Andrew’s deep experience enables Latitude to rapidly pinpoint key issues with difficult compounds, enabling the rapid development of toxicology and commercial formulations. His formulations are behind one approved drug, two NDA-stage drugs, and numerous clinical and preclinical stage projects. Andrew’s creative and inventive approach has led to over 25 issued and pending formulation patents, many of which list him as the sole inventor. Before founding Latitude, Andrew held positions of increasing responsibility at Bristol Myers Squibb Co., Immulogic, Inc., Selective Genetics, Inc., and IriSys, Inc. Andrew obtained his BS degree in pharmacy from Zhejiang University and his MS in PhD degrees in Pharmaceutical Sciences from St. John’s University in New York. Andrew is a registered pharmacist.
Norman K. Orida, PhD, MBA, Vice President of Business Development. Norman has over 20 years of experience as a researcher and business development executive in the pharmaceutical and medical device industries. Prior to joining Latitude in 2007, he held positions of increasing responsibility at Tanabe Seiyaku Co., Ltd., Medinox, Inc., Optimer Pharmaceuticals, Inc., and Curexo, Inc. In all the positions, he played key roles in the companies’ business development, licensing, and M&A activities. Norman received his A.B. degree in zoology from the University of California, Berkeley and his Ph.D. in developmental biology from the University of California, Irvine. He also received his MBA degree from the Sloan School of Management at the Massachusetts Institute of Technology.
Yali Tsai, PhD, RPh, Vice President of Project Development. Yali is a seasoned drug formulator who started her industrial career immediately after receiving her PhD in pharmaceutical sciences from the University of Southern California. Before joining Latitude in 2006, she has held positions of increasing rank and responsibility over the past 16 years at Vical, Inc., Abbott Laboratories, Inc., ISIS Pharmacueticals, Inc., and Pfizer, Inc. In these positions, she was actively involved in numerous formulation development projects related to oncology, virology, ophthalmology, and hospital products. At Latitude, her responsibility areas cover parenteral and ophthalmic formulation projects. Yali received her BS in Pharmacy from National Taiwan University and is also a registered pharmacist.
John Fan, PhD, Director of Formulation. John’s career has focused on drug formulation and manufacturing first as a postdoc at the University of Kentucky, then in industrial positions of increasing responsibility at IriSys, Inc., Paddock Laboratories, Inc., and Amylin Pharmaceuticals, Inc. John has over 10 years of hands-on formulation experience from numerous preformulation, deformulation, formulation development and transfer, and process scale up projects. In addition, John’s experience in cGMP manufacturing includes batch record preparation and review, QA/QC responsibilities, and stability testing. John received his PhD degree at the University of Utah and postdoctoral training at the University of Kentucky.
Hailiang Chen, PhD, Senior Scientist. Hailiang’s brings to Latitude his extensive expertise in achieving controlled and sustained release delivery profiles from novel delivery systems such as liposomes, microspheres, nanoparticles, nanoemulsions, and other dosage forms. Since arriving at Latitude in 2007, Hailiang has been a major contributor to the company’s preformulation, formulation development, process selection and scale-up functions. Hailiang received both his BS in Pharmacy and PhD in Pharmaceutics from Zhejiang University in China.
Stephen Wu, General Manager. Stephen has broad industry experience from accounting and management positions at financial institutions, large manufacturing companies, and R&D companies. Since joining Latitude in 2003, he has since served as the company’s General Manager, having responsibility for all aspects of Latitude’s accounting and administrative functions as well as the buildout of the company’s facilities and infrastructure.
NEWS!
Ms. Briana Erickson
Phone: 800-611-3388
www.PhytoMedical.com
PhytoMedical Technologies, Inc.
100 Overlook Drive, 2nd Floor
Princeton, NJ 08540
News Release
PhytoMedical Partners with Renowned Specialty Laboratory to Develop an IV Formulation For Its Successfully Tested Anti-Cancer Compound for Glioblastoma
LATITUDE Pharmaceuticals, Inc. is a leading provider of cutting edge drug formulation services and technologies to the pharmaceutical and biotech industries
Princeton, NJ - August 5, 2009 - PhytoMedical Technologies, Inc. (OTCBB: PYTO) (FWB: ET6), today announced their partnership with LATITUDE Pharmaceuticals, Inc. to develop an IV Formulation for its lead anti cancer compound for glioblastoma. LATITUDE Pharmaceuticals, Inc. is a widely recognized expert in the area of drug formulations and delivery systems. "Given LATITUDE's successful track record in formulation development, we are extremely pleased to have partnered with such an innovative group of experts," commented PhytoMedical, President, CEO, Greg Wujek. "The development and subsequent testing of the IV Formulation are key components in PhytoMedical's quest to provide physicians and their patients with an effective treatment option for this most difficult to treat and often deadly form of brain cancer."
"We are very happy to be chosen by PhytoMedical for this assignment because of our previous successes," noted LATITUDE's president, Dr. Andrew Chen. "Having the right formulation is instrumental to cost-effective, efficient, and expedient drug development. We look forward to contributing to the success of PhytoMedical's exciting compound."
Nearly two years ago PhytoMedical began the testing of several different anti cancer compounds which are based on the science of bis-intercalation, the process by which the anti-cancer compounds bind to the DNA of a cancer cell, disallowing replication and resulting in cell death. In a February press release outlining the results of a crucial in vivo efficacy and toxicity evaluation, it was announced that the Company's patented anti-cancer compound proved to be the least toxic yet extremely effective in controlling the growth of SF295 human glioblastoma xenografts.
In all cases where specimens were treated for human glioblastoma brain cancer using PhytoMedical's patented compound, researchers reported: a significant reduction in tumor size; prolonged lifespan of 46%-plus for the treated group versus the control group; notable enhanced chemotherapeutic effect of the compound; and even an observation of "tumor cured" in one of the specimens that had been carrying the deadly glioblastoma cancer.
"We look forward to working with the LATITUDE team and the evolvement of their role in assisting us with furthering the development our key anti cancer compound" stated Mr. Wujek.
About LATITUDE Pharmaceuticals, Inc.
LPI is a contract research organization and drug delivery company that provides innovative, leading-edge drug formulation services and technologies to the biotech and pharmaceutical industries. The company is recognized for its many successes in formulating insoluble drugs and for developing innovative approaches and intellectual property for its clients. For additional information, please visit www.latitudepharma.com
About PhytoMedical Technologies, Inc.
Interesting trade today: closing bid higher than last sale, & .06 offer dissapeared.
Closing mkt: .053-.066
some decent buying this morning, but pps knocked down on 200 shares. (lol)
Hoping for news "soon".
nite playing games > must have a trader (MM) in the stock.
2 days of strong selling, but the bright spot is someone bot 50k after the close.
Seller today. WTF! ;-(
Buyer today. .
HOPE HE/SHE KNOWS SOMET'IN!
Sorry to say, this puppy ain't go'in nowhere till we get news re final delivery system.
I believe the next news after that, MIGHT be some type of partnership for human testing,> or even a buyout by a bigger player in the cancer business.
glta
REASON FOR BUYERS:
July 1st , 2009
Letter from the President Q309
It has been a time of historical proportions that has changed the markets and industries forever, including both the pharmaceutical and biotechnology sectors. In the midst of all of this activity PhytoMedical continues to persevere with the successful execution of their business strategy. It is from here that I wanted to take this opportunity to provide you with an update on PhytoMedical's progress these past months. Therefore, I have taken the liberty of re-circulating our press releases from October 2008 to our most recent in order to provide you with a snapshot of our developmental progress.
The pharmaceutical industry is in the midst of reinventing itself, shifting from the costly strategy of acquiring a defined number of late-stage primary care compounds towards securing a large number of specialized early stage developmental opportunities. This shift bodes well for PhytoMedical as we continue to develop our anti-cancer compounds based upon the science of bis-intercalation.
During 2007-2008 we successfully conducted and completed a series of anti-cancer in vitro studies which justified our action to acquire the worldwide licensing rights from Dartmouth College in late 2008 and subsequently initiate the renewal of our Sponsored Research Agreement. Upon successful completion of the in vitro studies we progressed to the next phase of research initiating two variant in vivo toxicity and efficacy studies which began in late second quarter 2008. We announced in late October 2008 the successful results of the first phase of our anti-cancer in vivo studies specific to colon cancer. The second phase, specific to glioblastoma, began shortly afterwards and was completed in early Q109. Although both tests demonstrated favorable results the researchers reviewed the data collected from these important efficacy and toxicity tests, and surmised that PhytoMedical's anti-cancer compound(s) may "...have its selectivity in killing SF295 human glioblastoma cells." Comparatively, broad anti-cancer treatments may be less effective and carry greater risks and side-effects than compounds with the key ability to selectively target and kill specific cancer cells -- an important consideration for the treatment of cancers in vital organs such as the brain, where glioblastoma is exhibited. Given the associated costs and limited successful treatment options for treating glioblastoma, we are excited to be pursuing a selective treatment option for this deadly disease through the expansion of our research efforts. We are currently working on the development of our IV Formulation which is a vital step towards our Investigational New Drug (IND) preparation.
Additional developmental opportunities
PhytoMedical has developed a strong network amongst the pharmaceutical, biotechnology and academic science communities. It is from there that PhytoMedical continues to actively search and review other unique science and future partnerships.
Advisory Board
PhytoMedical's Advisory Board encompasses an experienced, dynamic group of experts that provide PhytoMedical with the necessary expertise to successfully progress their development in addition to searching and reviewing new opportunities.
Our Future
Given the strong industry network that PhytoMedical possesses we are constantly discussing the developmental progress of our technology with potential partners for future opportunities.
Industry Recognition
We are continually approached by all facets of the industry regarding the recent success of our development. Most recently we were featured in an article in Drug Discovery (http://www.drugdiscoverynews.com/index.php?newsarticle=2422).
We at PhytoMedical appreciate the continued support and encouragement and look forward to the future of providing successful treatment options for both the patient and physician. Thank you and I encourage you to keep in touch by visiting our website (www.phytomedical.com) and or contacting us directly at 1-800-611-3388.
Regards,
Greg Wujek
President, CEO
Someone cleaned out the .05 shares and is now bidding.
ELYSSE, great purchase. My dry is currently "out to dry" so can't play. There is a large dumper @ .05.
glty
Added some today at $.04. I will take my chances at this price and may buy some more.
On CNBC today an interview with CELLDEX ceo. (that is partnered with PFIZER). Of special note is that CELLDEX is purchasing CURAGEN for $94.5 MILLION. Thats $94,500,000!!!!!!
Guys and gals, I truly believe this, PYTO, is, prehaps, the golden opportunity we've been dreaming of being involved in!
Oh, in case the connection hasn't been made, CELLDEX is in the
BRAIN CANCER BUSINESS.
GLTA.
someone stepped up to the plate today and bot almost 100K @ .059. The seller immediately marked pps down to .0525 on 120 shares. LOL
looks like a seller is @ .07, although the offer posted is .08.
Maybe a market maker is now playing the stock.
I'm bidding "the bid" but couldn't get a share today.
then go right back up at the open...
you mean go down 65% 1 miinute before a planned halt?
elysse, last time I e mailed GW was the day DNDN news hit. My suggestion was that one day pyto could do the same.
GLTY
elysse, me too. Shouldn't be too much longer till some news is released on delivery. Hopefully new players will be attracted.
I sure have been accumulating on dips at these tag sale prices.
ELYSSE, are you still accumulating?? I've been picking up shares in the .07 area.
some nice up tics today. was hoping for news, but nothing yet.
my last conversation with GW indicated it will be the delivery formulation. After that, human testing.
GLTA
ps not me buying.
No real reason here to get too excited. most trades on bid side and very small buying on offer side.
there's always interesting things in BB 10-k's
btw, the liquidity i referred to wasnt neccessarily in this one, but it is welcomed nonetheless
10K was filedon 3/20/09. Some interesting things:
Form 10-K PHYTOMEDICAL TECHNOLOGIE For: Dec 31 Edgar Online
11:32 am March 20, 2009 http://xml.10kwizard.com/filing_raw.php?repo=tenk&ipage=6218036. Filed on: March 20, 2009. More
EddieH, "your lips to God's ears".
elysse, thanks for close today (if you were the one). I was out this afternoon.
Was out all day, but someone made sure the close was .09.
Thanks to whomever.!
I actually recently added a mere 300 shares near the end of the trading day at $.09(I believe the bid was $.07) more to make the stock price look better than anything else. lol
Followers
|
14
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
342
|
Created
|
02/15/06
|
Type
|
Free
|
Moderators |
PhytoMedical
Contact:
PhytoMedical Technologies, Inc.
800-611-3388
www.PhytoMedical.com
About PhytoMedical Technologies, Inc.
PhytoMedical Technologies, Inc. (Symbol: PYTO), together with its wholly owned subsidiaries, is an early stage research based biopharmaceutical company focused on the identification, acquisition, development and eventual commercialization of innovative plant derived pharmaceutical and nutraceutical compounds targeting cancer and diabetes.
An estimated 300 new drugs of world-wide importance, worth over $150 billion, still remain to be discovered amongst the 250,000 species of higher plants found on earth, of which less than 15% have been investigated for bioactive compounds.
Presently, twenty of the best selling drugs come from natural sources and 25% of all prescription drugs contain active compounds originally derived from or patterned after compounds derived from plants.
--------------------------------------------------------------------------------
Polyphenolic Compounds Increase Sugar Metabolism by a Factor of 20
Diabetes, which results from the body’s inability to produce enough insulin or use it efficiently, affects 18.2 million people in the United States, or 6.3% of the population (American Diabetes Association). The Centers for Disease Control and Prevention expects this number to rise to over 30 million by 2030. As the leading cause of end-stage renal disease, blindness and lower limb amputations, diabetes now costs the health care system over $132 billion each year.
While the causes of diabetes are not entirely clear, it is known that diet plays a key role in the prevention and cure of diabetes. In fact, research studies have shown that aqueous extracts of the most commonly consumed spice, cinnamon, improves the action of insulin and helps to control risk factors associated with diabetes including: glucose, insulin, cholesterol, triglycerides and related variables.
One study published in Diabetes Care, a journal of the American Diabetes Association, showed that as little as one gram a day of cinnamon – one-fourth of a teaspoon twice a day – can lower blood sugar by an average of 18 to 29 percent, triglycerides (fatty acids in the blood) by 23 to 30 percent, LDL (or “bad”) cholesterol by 7 to 27 percent and total cholesterol by 12 to 26 percent. Changes in HDL (“good”) cholesterol were not significant. Amazingly, the study found that the beneficial effects of cinnamon lasted for at least 20 days after people stopped taking it.
PhytoMedical is working towards synthesizing the active components found in cinnamon and characterizing their beneficial health effects.
--------------------------------------------------------------------------------
A New Class Of Antitumor Agents Designed To Bind To DNA And Kill Cancer Cells.
Cancer kills more than 1,500 Americans each day and is the second leading cause of death in America. Cancer is attributed to one in every four deaths nationally, and accounts for at least one in every ten dollars spent on healthcare. According to the American Cancer Society, 2006 estimates peg direct medical costs (the total of all health expenditures) at $78.2 billion and the total estimated cost of cancer (which includes indirect morbidity and mortality costs) at $206.3 billion.
Currently, at least 9.6 million Americans have been diagnosed with cancer according to National Cancer Institute estimates, with a staggering 1.4 million new cases expected by the end of this year. Despite spending more than $1 trillion to fight the disease in over three decades of research, over half a million Americans are expected to die of cancer this year, with the ‘lifetime risk’ of developing cancer still remaining high: In the US, men have a little less than 1 in 2 lifetime risk of developing cancer; for women the risk is a little more than 1 in 3.
In response, PhytoMedical is working in collaboration with scientists at Dartmouth College to develop new anti-cancer compounds. Dartmouth scientists have synthesized a novel class of antitumor agents with a cytotoxic affinity for cancer cells, designed to bind more tightly to cancer cell DNA than many conventional anticancer drugs by a process called bis-intercalation or “double binding,” much like a molecular staple. Because the DNA is the blueprint of life for the cancer cell, such binding stops the replication of the DNA, which prevents the growth of the cancer cell and it dies.
Working with Dartmouth scientists, PhytoMedical plans to improve upon the concept of bis-intercalation and will evaluate these new compounds against several different cancer cell lines, including prostate, lung, brain and bladder cancer.
http://www.PhytoMedical.com/Alerts-Index.asp
To view the full HTML text of this release, please visit:
http://www.PhytoMedical.com/IR/PressReleases/20060215-1.html
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |